Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The following inclusion criteria are consistent with information in the SYMLIN package insert and apply to insulin using patients with type 2 or type 1 diabetes who:~  * Have failed to achieve the desired or optimal level of glycemic control despite utilizing appropriate, individualized insulin regimens~ * Have A1C \<=9.0% within 3 months of study enrollment~ * Are receiving ongoing diabetes care under the guidance of a Health Care Provider (HCP) trained in the use of SYMLIN~Exclusion Criteria:~* The following exclusion criteria are consistent with the SYMLIN package insert and specifically exclude patients who:~  * Are poorly compliant with their current insulin regimen, as defined by their HCP~ * Are poorly compliant with prescribed blood glucose self monitoring, as defined by their HCP~ * Have experienced recurrent patient-ascertained severe hypoglycemia requiring assistance during the past 6 months~ * Have hypoglycemia unawareness~ * Have a confirmed diagnosis of gastroparesis~ * Require the use of drugs that stimulate gastrointestinal motility~ * Are female and pregnant or lactating and for whom the HCP determines the potential benefit does not justify the potential risk to the fetus or infant~ * Have been treated with SYMLIN within 3 months prior to study start

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Type 1 (Type: None): Patients with type 1 diabetes
- Type 2 (Type: None): Patients with type 2 diabetes

Based on this trial design, predict the completion outcome and termination type (if applicable).